集中度是否构成问题，取决于付款方转移成员或停止归因结果的速度，这主要看合同中测量窗口的条款，而非ARR占比本身。 数字健康公司面临的问题版本不同于通用版本。结果风险的签约速度快于公司验证自身承担能力的时间——12个月测量窗口对11个月销售周期——因此忽略风险收入占比的答案必然错误。分析必须从参与率和毛利率出发，而非从收入开始。
集中度是否构成问题，取决于付款方转移成员或停止归因结果的速度，这主要看合同中测量窗口的条款，而非ARR占比本身。 数字健康公司面临的问题版本不同于通用版本。结果风险的签约速度快于公司验证自身承担能力的时间——12个月测量窗口对11个月销售周期——因此忽略风险收入占比的答案必然错误。分析必须从参与率和毛利率出发，而非从收入开始。
占收入大头的风险收入份额是否危险，取决于参与率和结果窗口长度。如果付款方能在销售周期内重新定向归因或降低PMPM，风险立即显现。如果条款将付款与护理路径重构绑定，即使占比高，位置也更稳固。
陷阱在于大型风险合同通常伴随更差的经济条件：更低的PMPM、更严格的参与要求和更慢的结算，因此结果风险与利润压力同时到来。发展其他合同降低占比需要时间，更快的步骤通常是重新谈判风险条款，对测量窗口敞口定价。
还应区分基于归因结果和毛利率的ARR集中度与贡献集中度。两者可能反向变动，只有后者决定失去合同是否真正需要削减成本。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 单一合同在风险条款下占ARR大头
✓ 该合同的PMPM明显低于其余账簿，或参与要求更高
✓ 失去该合同将迫使立即调整已入组成员项目，而非分阶段计划
通常会让情况更糟的做法。 追逐新客户以稀释占比，这会延长销售周期并增加成本，而结果依赖仍未解除。
It is for you if you run or finance a digital health company and one customer exceeds a quarter of revenue. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
没有单一阈值本身有意义。关键在于他们能多快替换你，以及替换后固定成本会发生什么。两者都可以回答。
很少仅因集中度拒绝，通常因利润率。如果最大账户也是定价最差的，集中度问题与利润率问题有同一解法。
提高他们离开的成本，并重新定价敞口。发展第二细分市场是正确的长期答案，但在实际通知期内并无帮助。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית